CUSTOMFLEX® ARTIFICIALIRIS receives Transitional Pass‐through Payment Status
CMS grants pass‐through payment status to the first and only FDA‐approved iris prosthesis, allowing greater access for patients
CINCINNATI, Ohio -- VEO Ophthalmics, LLC, today announced that the CUSTOMFLEX® ARTIFICIALIRIS has been approved by the Center for Medicare and Medicaid Services (CMS) for transitional pass‐through payment status, effective January 1, 2020. The HCPCS code for the CUSTOMFLEX® ARTIFICIALIRIS that is associated with pass‐through payment is: C1839 Iris prosthesis.
The approval by CMS for transitional pass‐through payment was under the new alternative pathway for Breakthrough devices. Ron Gilliland, President and CEO of VEO Ophthalmics stated, “Since receiving FDA approval, the CUSTOMFLEX® ARTIFICIALIRIS has helped many patients suffering from symptomatic aniridia. The decision by CMS to grant pass‐through payment status will now make this unique technology available to more patients in the U.S.”
The CUSTOMFLEX® ARTIFICIALIRIS is the only iris prosthesis available in the United States, receiving FDA approval on May 30, 2018 for use in children and adults for the treatment of iris defects resulting from congenital aniridia, acquired defects or other conditions associated with a completely or partially missing or damaged iris.
People may have a damaged or missing iris from birth or as a result of ocular injuries or other trauma, disease, or surgery. They struggle to cope with symptoms related to the eye’s inability to control the level of incoming light, including light sensitivity, glare, halos, reading difficulty, and problems with night driving. Many face above‐average risk of glaucoma and cataract formation as well.
About VEO Ophthalmics
Located in Cincinnati, Ohio, VEO Ophthalmics, LLC, is a developer and distributor of ophthalmic surgical technologies. VEO focuses on improving patient care by partnering with leading ophthalmic surgeons to develop innovative tools for today’s challenging surgical environment. Close relationships with ophthalmic healthcare customers and business partners help VEO ensure that its products and service experience meet the highest standards.
To learn more, visit VEO at www.veo‐ophthalmics.com.
-
Most popular related searches
Related news
-
U.S. FDA approves Xarelto to treat venous thromboembolism (VTE) and to prevent VTE in children
Xarelto is the only Factor Xa anticoagulant FDA approved for pediatric patients and offers a flexible weight-based dosing Xarelto is available in both oral tablet and liquid suspension formulations for use in appropriate children less than 18 years of age Convenient liquid formulation advances standard of care for children; alleviates administration challenges found with injectable alternatives The U.S. Food and Drug Administration (FDA) has approved two pediatric indications for Xarelto (rivaroxaban): the...
-
Phase III trial with Nubeqa (darolutamide) in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer
ARASENS trial demonstrates an increase in overall survival evaluating darolutamide in combination with docetaxel and androgen deprivation therapy (ADT) compared to docetaxel and ADT, a standard of care in metastatic hormone-sensitive prostate cancer (mHSPC) / Bayer plans to present these pivotal data at a forthcoming scientific congress and to discuss them with health authorities / ARASENS is part of broad development program for darolutamide which includes another ongoing Phase III trial in mHSPC, ARANOTE,...
-
InspireMD Receives Reimbursement Approval for CGuard™ Embolic Prevention System from the French National Authority for Health
InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announced that its CGuard EPS stent system has received a positive opinion from the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDIMTS) of the French National Authority for Health (HAS) regarding reimbursement in France, and the CGuard EPS is being added to the list of reimbursed...
-
IFEMA MADRID will host the Congress of the European Association for Cranio Maxillo Facial Surgery in the Palacio Municipal
This biennial congress comes to Madrid as the Spanish Professor Julio Acero occupies the Presidency of the Association, and it expects to host more than 2.000 attendees from 70 countries. This edition will mean the return to the face-to-face format after the last appointment of the Congress, celebrated in Munich in 2018, and the virtual edition celebrated last summer after the impossibility of holding it in person in Paris in 2020. IFEMA MADRID continues working for the reactivation of the MICE sector in...
-
Artugen Announces Five Abstracts Published in the 30th ECCMID Abstract Book
Clostridioides difficile infection (CDI) causes the most common healthcare-associated infections in the United States and the most frequent hospital-acquired intestinal infection in Europe and worldwide. The prevalence of C. difficile outbreaks since the early 2000s has resulted in higher morbidity and mortality along with increasing medical costs throughout the world. Without effective antibiotics and therapeutics for the prevention and treatment of infections, many of the achievements of modern medicine such...
Customer comments
No comments were found for CUSTOMFLEX® ARTIFICIALIRIS receives Transitional Pass‐through Payment Status. Be the first to comment!